Erste Asset Management Gmb H Global Blood Therapeutics, Inc. Transaction History

Erste Asset Management Gmb H

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 26, 2024	SELL	N/A	-58,000 Closed	0 $0
Q4 2022 Nov 26, 2024	SELL	$0.0 - $68.49 $0 - $3.97 Million	-58,000 Closed	0 $0
Q3 2022 Nov 26, 2024	BUY	$32.4 - $68.18 $1.88 Million - $3.95 Million	58,000 New	58,000 $3.95 Billion
Q2 2022 Nov 26, 2024	BUY	$22.3 - $37.39 $936,600 - $1.57 Million	42,000 Added 262.5%	58,000 $1.87 Billion
Q1 2022 Nov 22, 2024	BUY	$25.68 - $35.59 $115,560 - $160,155	4,500 Added 8.41%	58,000 $2.03 Billion
Q4 2021 Nov 22, 2024	BUY	$24.9 - $40.26 $1.33 Million - $2.15 Million	53,500 New	53,500 $1.62 Billion
Q3 2020 Nov 22, 2024	BUY	$52.76 - $74.49 $2.82 Million - $3.99 Million	53,500 New	53,500 $2.89 Billion
Q1 2020 Nov 22, 2024	SELL	$41.72 - $87.2 $429,716 - $898,160	-10,300 Reduced 16.14%	53,500 $2.78 Billion
Q4 2019 Nov 22, 2024	BUY	$45.7 - $81.86 $2.92 Million - $5.22 Million	63,800 New	63,800 $5.05 Billion
Q2 2019 Nov 22, 2024	BUY	$52.6 - $63.29 $1.83 Million - $2.2 Million	34,800 Added 120.0%	63,800 $3.44 Billion
Q1 2019 Nov 22, 2024	BUY	$39.99 - $53.48 $1.16 Million - $1.55 Million	29,000 New	29,000 $1.51 Billion
Q4 2018 Nov 26, 2024	BUY	$31.54 - $46.67 $504,640 - $746,720	16,000 New	16,000 $638 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.